Korea Institute of Science and Technology

Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Korea Research Institute of Chemical Technology

Korea Research Institute of Bioscience and Biotechnology

Catholic University Industry Academic Cooperation Foundation

Hanmi Holdings Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Young Jin Ham

Hwan Geun Choi

Tae Bo Sim

Jung Mi Hah

Young Gil Ahn

Hwan Mook Kim

Maeng Sup Kim

Kyung Ho Yoo

Jung Beom Son

Chang Hyun Oh

Seok Jong Kang

Jae Yul Choi

Hwan Oh Kim

Gwan Sun Lee

Eun Young Kim

Kwee Hyun Suh

Ji Yeon Song

In Hwan Bae

Tae Woo Kim

Seung Hyun Jung

Mi Young Cha

Young Hee Jung

Seo Hee Kim

Eun Jin Jun

Dong-sik Park

Jung Hun Lee

Jong Woo Kim

Dong-wook Kim

Jae Chul Lee

Se Young Kim

Dong Sik Park

Sung Yun Cho

Dong Cho Han

Jae Du Ha

Keuk Chan Bang

Byoung Mog Kwon

Mi Kyoung Lee

So Ha Lee

Jung-Hun Lee

Tae Hun Song

Myoung Sil Ko

Wha Il Choi

Eun Ju Jeon

In Ho Yang

Wha Ii Choi

Ji Hyeon Gong

Kyu Hang Lee

Chang In Kim

Eun Young Uman Jugong Apt 406-1302 Kim

Ji Hyeon Hwanggol Jugong Apt 130-2002 Gong

The present invention relates to an imidazopyridazine compound having cell growth inhibitory activity, and a pharmaceutical composition for preventing or treating cancer or a tumor including the same. The imidazopyridazine compound of Chemical Formula 1 according to the present invention has excellent cell growth inhibitory activity, and thus can be favorably used as a preventive or therapeutic agent for cancer or a tumor.

Imidazopyridazine compound

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

Pyrimidine compound and pharmaceutical use thereof

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase

A substituted thieno pyrimidine compound of Formula 1, pharmaceutically acceptable salts and a pharmaceutical composition thereof is provided.  The compound of Formula 1 exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction. The compound of Formula 1 and its compositions are useful for the prevention and treatment of diseases caused by abnormal cell growth including cancer.

2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases

Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel indole compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

1,6-disubstituted indole compounds as protein kinase inhibitors

Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.

Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient

Disclosed are a 1,3,6-substituted indole compound having inhibitory activity for protein kinases, a pharmaceutically acceptable thereof, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth including the compound as an active ingredient. Since the novel indole compound exhibits superior inhibitory activity for various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

1,3,6-substituted indole derivatives having inhibitory activity for protein kinase

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.

Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof

The bioavailability of an anticancer agent is enhanced when the anticancer agent is administered together with a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same

Growing community of inventors

Seoul, South Korea

Young Jin Ham